Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018: Ken Research


Refractory diseases are those diseases that did not respond to the treatment as has surfaced again. Relapsed chronic lymphocytic leukaemia means that the cancer did not respond to the treatment and has recurred reaching remission. Treatment for this will include chemotherapy based on its response the first time. If the disease becomes resistant to chemotherapy, other drugs are used to treat leukemia. Other treatment options include targeted therapy, surgery, radiation therapy and supportive therapy.

Clinical trials are conducted in medical research labs to find better ways to prevent and treat diseases or diagnose them. They give solutions on the medical approaches suitable for certain illness to a certain group of people specifically. These trials help a great deal in making healthcare decisions. Since they answer scientific questions, these trials are required to be carried on under strict and scientific standards that protect the interests of the patients. They are also the final and the most important stage of clinical research and development. Clinical trials for drugs take place in four phases- first, they test an experimental drug on a few people and study the effects; second, they test the drug on more people than in Phase 1 which may extend up to years; third, they include many other participants to test for safety and efficacy and study the side effects deeper than in Phase 2; fourth, getting approval of the usage of drug from the relevant authority.

Ken Research’s Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018 gives an overview of the global clinical trials landscape and top-level data related to clinical trials by Regio, Country (G7 and E7), Trial Status, trial Phase, Sponsor type and End point status. The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company and all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for their non-accomplishments. It provides enrolment trends for the past five years and the latest news relating to these trials for the past three months. The companies involved in the clinical trials of Refractory Chronic Lymphocytic Leukemia are AbbVie Inc, F. Hoffmann-La Roche Ltd, Celgene Corp, Novartis AG, Johnson & Johnson, AstraZeneca Plc, Gilead Sciences Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb Co and Sanofi. The report will enhance the decision- making capabilities and helps to create an effective counter strategy to gain competitive advantage.

For more information, click on the link below:

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

+91 9015378249